"Lilly halted a Phase clinical trial of semagacestat in August after it worsened the condition of patients."
This was David's shortcoming. He shoud not have stopped the portfolio moving.
http://www.ibj.com/eli-lilly-neuroscience-chief-resigns/PARAMS/article/25551
This was David's shortcoming. He shoud not have stopped the portfolio moving.
http://www.ibj.com/eli-lilly-neuroscience-chief-resigns/PARAMS/article/25551